



For Immediate Release

Vaxart to Present at Leerink Partners Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Feb. 4, 2016 — Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today it will present at the Leerink Partners Global Healthcare Conference at The Waldorf Astoria Hotel in New York City.

Wouter Latour, M.D., chief executive officer of Vaxart, will give a presentation on Wednesday, Feb. 10, 2016 at 3:30 p.m. Eastern Standard Time. The presentation will cover Vaxart's proprietary oral vaccine platform and latest developments on its tablet vaccines for seasonal influenza, respiratory syncytial virus (RSV) and norovirus.

For conference information and investor registration to attend the Vaxart presentation, please visit <http://www.leerink.com/>.

About Vaxart

Vaxart is a clinical-stage company developing tablet vaccines based on its proprietary oral vaccine platform. The lead programs are oral vaccines for seasonal influenza, RSV and norovirus. Vaxart vaccines are administered using convenient room temperature-stable tablets that can be stored and shipped without refrigeration, are easy to administer, eliminate risk of needle-stick injury and medical waste associated with injectable vaccines. The company is backed by Care Capital, Finney Capital, Quantum Technology Partners, Life Science Angels, Sand Hill Angels and Bay Partners. For more information, please visit www.vaxart.com.

###

CONTACT:

Katie Hogan

WCG

415.658.9745

khogan@wcgworld.com